Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis

Pei-Jian Peng,1,* Hua Cheng,2,* Xue-Qing Ou,3 Lin-Juan Zeng,1 Xuan Wu,4 Yu-Meng Liu,5 Zhong Lin,1 Yan-Na Tang,1 Si-Yang Wang,3 Hong-Yu Zhang,1 Zhi-Bin Chen3 1Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiation Oncology, The Fifth Affiliated Hospital of Sun-Yat-Sen University, Zhu Hai, Guangdong Province, People's Republic of China; 4Department of Medical Oncology, Cancer Center, Sun-Yat-Sen University, Guangzhou, People's Republic of China; 5Department of Oncology, the People's Hospital of Zhongshan City, Zhongshan, Guangdong Province, People's Republic of China *These authors contributed equally to this work Purpose: This retrospective study evaluates the efficacy and safety of S-1 chemotherapy for recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy. Patients and methods: Thirty-nine patients with recurrent and metastatic nasopharyngeal carcinoma who failed previous platinum-based chemotherapy received oral S-1 chemotherapy (twice daily from day 1 to 14) every 3 weeks. The dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA